NEW YORK (TheStreet) -- Gilead Sciences
(GILD - Get Report) crushed analysts' bottom line expectations while also beating on revenue estimates, which grew 136% year-over-over.
This stock sells at just nine times forward estimates, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued on CNBC's "Cramer's Mad Dash" segment.
The company's drug, Sovaldi, is a cure for hepatitis C, and could go on to be the largest drug of all time, co-host David Faber added.
Read More: Blue Chip Thursday: Caterpiller, 3M, Ford, GM, Plus Three Homebuilders to Report
Sales for the drug will likely run higher than the suggested $10 billion annual run-rate, Cramer said.
The company was "very humble" about its results -- perhaps too humble -- and should continue to see long-term growth, as many future patients do not yet realize they have hep. C, Cramer concluded.
-- Written by Bret Kenwell in Petoskey, Mich.
Read More: Melvin: Wait for Quality and Price to Meet